Literature DB >> 9484360

Estimation of the temporal probability of human immunodeficiency virus (HIV) dementia after risk stratification for HIV-infected persons.

A I Qureshi1, D L Hanson, J L Jones, R S Janssen.   

Abstract

We developed a scheme using routinely available data to estimate the risk of human immunodeficiency virus (HIV) dementia in HIV-infected persons over time. We performed a longitudinal review of medical records from more than 100 medical facilities in 11 U.S. cities. A total of 19,462 HIV-infected persons without history of dementia enrolled in a multi-institution survey. The main outcome measure was the development of HIV dementia (1987 case definition) during the median follow-up period of 17 months (range, 1 to 72 months). Of 19,462 HIV-infected persons, HIV dementia developed in 880 persons (4.5%; 2.6% per person-year). The strongest predictors of HIV dementia were CD4+ T-lymphocyte count, anemia, and AIDS-defining infections or cancer. The 2-year probability of HIV dementia was highest for persons who had a CD4+ T-lymphocyte count of fewer than 100 cells/microL and an AIDS-defining illness or anemia or both (18.6 to 24.9%). Intermediate risk was observed in persons with CD4+ T-lymphocyte count of 100 to 199 cells/microL and an AIDS-defining illness or anemia or both or in persons with a CD4+ T-lymphocyte count of fewer than 100 cells/microL but without another risk factor (2-year probability, 10.4 to 15.2%). The 2-year probability that HIV dementia would develop was lowest (1.0%) for persons with CD4+ T-lymphocyte count of more than 200 cells/microL and no other risk factors. Risk stratification using routine clinical information provides information that may prove useful in patient care decisions.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9484360     DOI: 10.1212/wnl.50.2.392

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  4 in total

1.  Genome-wide association study of neurocognitive impairment and dementia in HIV-infected adults.

Authors:  Andrew J Levine; Susan Service; Eric N Miller; Sandra M Reynolds; Elyse J Singer; Paul Shapshak; Eileen M Martin; Ned Sacktor; James T Becker; Lisa P Jacobson; Paul Thompson; Nelson Freimer
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2012-05-24       Impact factor: 3.568

2.  CCL3 genotype and current depression increase risk of HIV-associated dementia.

Authors:  Andrew J Levine; Elyse J Singer; Janet S Sinsheimer; Charles H Hinkin; Jeanette Papp; Sugandha Dandekar; Allison Giovanelli; Paul Shapshak
Journal:  Neurobehav HIV Med       Date:  2009-11

3.  Anemia and Red Blood Cell Indices Predict HIV-Associated Neurocognitive Impairment in the Highly Active Antiretroviral Therapy Era.

Authors:  Asha R Kallianpur; Quan Wang; Peilin Jia; Todd Hulgan; Zhongming Zhao; Scott L Letendre; Ronald J Ellis; Robert K Heaton; Donald R Franklin; Jill Barnholtz-Sloan; Ann C Collier; Christina M Marra; David B Clifford; Benjamin B Gelman; Justin C McArthur; Susan Morgello; David M Simpson; J A McCutchan; Igor Grant
Journal:  J Infect Dis       Date:  2015-12-21       Impact factor: 5.226

Review 4.  The role of host genetics in the susceptibility for HIV-associated neurocognitive disorders.

Authors:  Andrew J Levine; Elyse J Singer; Paul Shapshak
Journal:  AIDS Behav       Date:  2008-02-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.